Bristol-Myers Squibb Stock Price. Everything You Need To Know About The Bristol-Myers Squibb Stock!
What is Bristol-Myers Squibb Stock Price. Everything You Need To Know About The Bristol-Myers Squibb Stock!?
Bristol Myers Squibb Co. is a New York-based biopharmaceutical company engaged in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company's range of therapeutic classes includes oncology, immunology, cardiovascular, and fibrosis. Bristol Myers Squibb employs around 32,200 full-time employees. The firm's product line includes chemically synthesized or small molecule drugs as well as biologics produced from biological processes. Biologics are administered to patients through injections or infusion. Bristol Myers Squibb's biopharmaceutical products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude, and Breyanzi. To stay informed about Bristol Myers Squibb's performance, you may want to keep an eye on its share price, market cap, and stock price today. You can also check stocks share price today and premarket data. If you're interested in investing in Bristol Myers Squibb, you may also want to know the price of its shares in Malaysia. The company sells its products to a range of customers, including wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. Additionally, Bristol Myers Squibb has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. So, the company's future prospects may impact its share price and stock price.
Bristol-Myers Squibb Stock Price. Everything You Need To Know About The Bristol-Myers Squibb Stock! performance
How To Invest In Bristol-Myers Squibb Company Stock From Malaysia, Thailand, Indonesia & Vietnam
Are you interested in investing in Bristol-Myers Squibb from Malaysia, Thailand, Indonesia, or Vietnam? Look no further, as Zorion offers a convenient and user-friendly platform for retail investors like you to invest in real US stocks, including Bristol-Myers Squibb. Our investment insights and recommendations will help you make informed decisions about your investment portfolio. Additionally, we provide access to valuable resources and educational materials to further enhance your investment knowledge. Start investing in Bristol-Myers Squibb and grow your wealth with Zorion today. Take advantage of this opportunity and maximize your potential returns.
How To Buy Bristol-Myers Squibb Company Stock From Malaysia, Thailand, Indonesia & Vietnam
If you're a retail investor in Malaysia, Thailand, Indonesia, or Vietnam, and you're looking to invest in Bristol-Myers Squibb, you're in the right place. At Zorion, we provide you with the tools and resources to make informed decisions about your investments. Bristol-Myers Squibb is a renowned pharmaceutical company focused on discovering, developing, and delivering innovative medicines to patients worldwide. With our investment insights and recommendations, you can easily navigate the process of buying Bristol-Myers Squibb stock from your country. Access our educational materials to enhance your investment knowledge and start investing in this leading pharmaceutical company with confidence.
Bristol-Myers Squibb Company Analytics and Performance
BMY: A Company in the LIFE SCIENCES Sector and PHARMACEUTICAL PREPARATIONS Industry
Discover Bristol-Myers Squibb Company (BMY), a prominent player in the LIFE SCIENCES sector, specifically within the PHARMACEUTICAL PREPARATIONS industry. As a Common Stock, BMY has a strong presence not only in the United States but also in various countries around the world, including its home base USA.
BMY Financial Performance: Key Ratios and Market Indicators
As of the latest quarter ending 2023-09-30, BMY boasts an EBITDA of 18448331000 and a trailing price-to-earnings ratio (PE ratio) of 12.59. The forward PE ratio stands at 6.75, which indicates stocks potential in earnings. BMY's price-to-sales ratio (TTM) is 2.202, and the price-to-book ratio is 4.494. The company's enterprise value-to-revenue and enterprise value-to-EBITDA ratios are 2.901 and 7.0, respectively.
BMY Stock Stability: Analyzing Marketing Volatility and Trends
BMY stock performance showcases a beta of 0.371, highlighting moderate volatility. The 52-week high and low prices are 70.68 and 47.58, respectively, with a 50-day moving average of 50.4 and a 200-day moving average of 58.24. With 2034760000 shares outstanding, BMY demonstrates strong performance in the market.
BMY Dividends: Current Yields and Shareholder Value
In terms of dividends, Bristol-Myers Squibb Company has a dividend per share of 2.31 and a dividend yield of 0.0493. The company's most recent dividend date was 2024-02-01, and the ex-dividend date was 2024-01-04. BMY's financials reveal a book value of 14.26 and earnings per share (EPS) of 3.87, with a diluted EPS (TTM) of 3.87.
BMY Revenue and Profitability: Unveiling the Company's Financial Strength
BMY revenue per share (TTM) is 21.75, and its total revenue (TTM) amounts to 45006000000. The company's gross profit (TTM) is 36378000000. BMY's profit margin stands at 0.178, while the operating margin (TTM) is 0.17. The return on assets (TTM) and return on equity (TTM) are 0.0559 and 0.267, respectively.
BMY Growth Prospects: Earnings Growth and Analyst Expectations
BMY has experienced quarterly earnings growth (YOY) of -0.087, but its quarterly revenue growth (YOY) remains stagnant at 0.006. Analysts have set a target price of 56.55 for Bristol-Myers Squibb Company stock.
Want To Buy Bristol-Myers Squibb Company Stock From Malaysia, Indonesia, Thailand or Philippines? You may also be interested in: